Literature DB >> 26442458

Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review.

Jonathan Yap1, Fang Yi Lim2, Fei Gao1,3, Ling Li Teo2, Carolyn Su Ping Lam1,4, Khung Keong Yeo1,3.   

Abstract

BACKGROUND: Functional status assessment is the cornerstone of heart failure management and trials. The New York Heart Association (NYHA) classification and 6-minute walk distance (6MWD) are commonly used tools; however, the correlation between them is not well understood. HYPOTHESIS: We hypothesised that the relationship between the NYHA classification and 6MWD might vary across studies.
METHODS: A systematic literature search was performed to identify all studies reporting both NYHA class and 6MWD. Two reviewers independently assessed study eligibility and extracted data. Thirty-seven studies involving 5678 patients were included.
RESULTS: There was significant heterogeneity across studies in 6MWD within all NYHA classes: I (n = 16, Q = 934.2; P < 0.001), II (n = 25, Q = 1658.3; P < 0.001), III (n = 30, Q = 1020.1; P < 0.001), and IV (n = 6, Q = 335.5; P < 0.001). There was no significant difference in average 6MWD between NYHA I and II (420 m vs 393 m; P = 0.416). There was a significant difference in average 6MWD between NYHA II and III (393 m vs 321 m; P = 0.014) and III and IV (321 m vs 224 m; P = 0.027). This remained significant after adjusting for region of study, age, and sex.
CONCLUSIONS: Although there is an inverse correlation between NYHA II-IV and 6MWD, there is significant heterogeneity across studies in 6MWD within each NYHA class and overlap in 6MWD between NYHA I and II. The NYHA classification performs well in more symptomatic patients (NYHA III/IV) but less so in asymptomatic/mildly symptomatic patients (NYHA I/II). Nonetheless, the NYHA classification is an easily applied first-line tool in everyday clinical practice, but its potential subjectivity should be considered when performing comparisons across studies.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26442458      PMCID: PMC6490728          DOI: 10.1002/clc.22468

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  26 in total

1.  Does Angiotensin Receptor Neprilysin Inhibitor (ARNI) Improve Functional Capacity Assessed by 6 Minutes Walking Test?

Authors:  Merce Faraudo; Paola Beltran; Roman Freixa; Elisabet Mena; Olga Guri; Anna Contra; Luís Miguel Ceresuela; Josep Masip
Journal:  Eur Cardiol       Date:  2017-12

Review 2.  Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.

Authors:  Ravi B Patel; Muthiah Vaduganathan; Stephen J Greene; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-06-26       Impact factor: 15.534

Review 3.  Biomarker definitions and their applications.

Authors:  Robert M Califf
Journal:  Exp Biol Med (Maywood)       Date:  2018-02

4.  Using Physical Function to Predict Hospital Readmission within 1 Year in Patients with Heart Failure.

Authors:  Hiroaki Teramatsu; Junichiro Shiraishi; Yasuyuki Matsushima; Masaru Araki; Tetsuya Okazaki; Satoru Saeki
Journal:  Prog Rehabil Med       Date:  2019-10-19

5.  Impact of Mechanical Circulatory Support on Exercise Capacity in Patients With Advanced Heart Failure.

Authors:  Janice Huang; Barry J McDonnell; Justin S Lawley; Jessica Byrd; Eric J Stöhr; William K Cornwell
Journal:  Exerc Sport Sci Rev       Date:  2022-10-01       Impact factor: 6.642

6.  Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study.

Authors:  Salma Charfeddine; Hassen Ibnhadjamor; Jihen Jdidi; Slim Torjmen; Salma Kraiem; Amine Bahloul; Ahmed Makni; Nesrine Kallel; Nedia Moussa; Mariem Boudaya; Imen Touil; Aiman Ghrab; Jamel Elghoul; Zeineb Meddeb; Yamina Thabet; Kais Ben Salem; Faouzi Addad; Kamel Bouslama; Sami Milouchi; Rania Hammami; Salem Abdessalem; Leila Abid
Journal:  Front Cardiovasc Med       Date:  2022-05-12

7.  Determinants of maximal oxygen uptake in patients with heart failure.

Authors:  Javier Roibal Pravio; Eduardo Barge Caballero; Cayetana Barbeito Caamaño; Maria Jesus Paniagua Martin; Gonzalo Barge Caballero; David Couto Mallon; Patricia Pardo Martinez; Zulaika Grille Cancela; Paula Blanco Canosa; Jose Manuel García Pinilla; Jose Manuel Vázquez Rodríguez; Maria Generosa Crespo Leiro
Journal:  ESC Heart Fail       Date:  2021-03-27

8.  An Alternative Prediction Equation for Evaluation of Six-Minute Walk Distance in Stable Coronary Artery Disease Patients.

Authors:  Helena Lenasi; Ana Novak; Borut Jug; Edvin Dervišević; Damir Karpljuk; Mateja Videmšek; Maroje Sorić; Vedran Hadžić
Journal:  Front Physiol       Date:  2022-03-31       Impact factor: 4.566

9.  Assessing right ventricular function in pulmonary hypertension patients and the correlation with the New York Heart Association (NYHA) classification.

Authors:  Xiaoke Shang; Shuna Xiao; Nianguo Dong; Rong Lu; Lijun Wang; Bin Wang; Yousan Chen; Liang Zhong; Mei Liu
Journal:  Oncotarget       Date:  2017-07-05

10.  Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Soung Hun Park; Catherine L Jarrett; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.